Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Management of patients with multidrug-resistant tuberculosis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Tuberculosis case finding and mortality prediction: added value of the clinical TBscore and biomarker suPAR

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Diabetes-related tuberculosis in Denmark: effect of ethnicity, diabetes duration and year of diagnosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Chronic bronchitis: so much more than just a smoker's cough

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Can tuberculosis case finding among health-care seeking adults be improved? Observations from Bissau

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The EuroSIDA study: 25 years of scientific achievements

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • C Lange
  • R E Aarnoutse
  • J W C Alffenaar
  • G Bothamley
  • F Brinkmann
  • J Costa
  • D Chesov
  • R van Crevel
  • M Dedicoat
  • J Dominguez
  • R Duarte
  • H P Grobbel
  • G Günther
  • L Guglielmetti
  • J Heyckendorf
  • A W Kay
  • O Kirakosyan
  • O Kirk
  • R A Koczulla
  • G G Kudriashov
  • L Kuksa
  • F van Leth
  • C Magis-Escurra
  • A M Mandalakas
  • B Molina-Moya
  • C A Peloquin
  • M Reimann
  • R Rumetshofer
  • H S Schaaf
  • T Schön
  • S Tiberi
  • J Valda
  • P K Yablonskii
  • K Dheda
View graph of relations

The emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampicin and isoniazid) represents a growing threat to public health and economic growth. Never before in the history of mankind have more patients been affected by MDR-TB than is the case today. The World Health Organization reports that MDR-TB outcomes are poor despite staggeringly high management costs. Moreover, treatment is prolonged, adverse events are common, and the majority of affected patients do not receive adequate treatment. As MDR-TB strains are often resistant to one or more second-line anti-TB drugs, in-depth genotypic and phenotypic drug susceptibility testing is needed to construct personalised treatment regimens to improve treatment outcomes. For the first time in decades, the availability of novel drugs such as bedaquiline allow us to design potent and well-tolerated personalised MDR-TB treatment regimens based solely on oral drugs. In this article, we present management guidance to optimise the diagnosis, algorithm-based treatment, drug dosing and therapeutic drug monitoring, and the management of adverse events and comorbidities, associated with MDR-TB. We also discuss the role of surgery, physiotherapy, rehabilitation, palliative care and smoking cessation in patients with MDR-TB. We hope that incorporating these recommendations into patient care will be helpful in optimising treatment outcomes, and lead to more MDR-TB patients achieving a relapse-free cure.

Original languageEnglish
JournalThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
Volume23
Issue number6
Pages (from-to)645-662
Number of pages18
ISSN1027-3719
DOIs
Publication statusPublished - 1 Jun 2019

ID: 59238545